Packages (Simulation)
![Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay)](/upload/static/product/LM.jpg)
Reagent Preparation
![Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay)](/upload/static/reagent/TLMB.jpg)
Image (I)
Image (II)
Certificate
![Certificate](/upload/static/ISO13485.jpg)
![Certificate](/upload/static/ce-1.jpg)
Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay)
PLAU; ATF; URK; UK; UP-A; Abbokinase; Urokinase-Type Plasminogen Activator
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA140Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample TypeSerum, plasma and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 405
US$ 420
US$ 443
US$ 475
US$ 506
US$ 552
US$ 622
Result
For more details, please contact local distributors! US$ 778 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 83-102 | 93 |
EDTA plasma(n=5) | 85-92 | 88 |
heparin plasma(n=5) | 78-102 | 97 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-88% | 94-102% | 92-101% | 84-99% |
EDTA plasma(n=5) | 83-92% | 92-105% | 89-97% | 81-93% |
heparin plasma(n=5) | 91-98% | 80-93% | 81-102% | 92-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:uPA) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice SpringerLink: f3w831267267p277 |
Biomarker insights | Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD) PubMed: PMC3762604 |
Oncol Rep. | Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma Pubmed:25421538 |
International Journal of Oncology | 1, 25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway Pubmed:26782341 |
Biochemical and Biophysical Research Communications | Methylation of neurofilament light polypeptide promoter is associated with cell invasion and metastasis in NSCLC Pubmed:26801564 |
39 | Cytokine and Estrogen Stimulation of Endothelial Cells Augments Activation of the Surface-Bound Prekallikrein-High Molecular Weight Kininogen Complex: Implications for Hereditary Angioedema (HAE): 814 article:S0091-6749(15)02643-3 |
SCIENCE & TECHNOLOGY | A Study Protocol: Spinal Morphology, Physical Performance, Quality of Life and Biochemical Markers in Adults at Risk of Osteoporotic Fractures 59f7c85aaca272607e2d8d7a |
Oncotarget | Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma pubmed:28404945 |
Journal of allergy and clinical immunology | Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema. pubmed:27826093 |
Molecular Medicine Reports | Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro Pubmed:29328476 |
Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug … Pubmed:35121390 |
Cellular and Molecular Life Sciences | IL4 stimulated macrophages promote axon regeneration after peripheral nerve injury by secreting uPA to stimulate uPAR upregulated in injured axons Pubmed:35536429 |
Catalog No. | Related products for research use of Mus musculus (Mouse) Organism species | Applications (RESEARCH USE ONLY!) |
APA140Mu61 | Active Plasminogen Activator, Urokinase (uPA) | Cell culture; Activity Assays. |
RPA140Mu01 | Recombinant Plasminogen Activator, Urokinase (uPA) | Positive Control; Immunogen; SDS-PAGE; WB. |
APA140Mu62 | Active Plasminogen Activator, Urokinase (uPA) | Cell culture; Activity Assays. |
RPA140Mu02 | Recombinant Plasminogen Activator, Urokinase (uPA) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA140Mu01 | Polyclonal Antibody to Plasminogen Activator, Urokinase (uPA) | WB; IHC; ICC; IP. |
PAA140Mu02 | Polyclonal Antibody to Plasminogen Activator, Urokinase (uPA) | WB; IHC; ICC; IP. |
SEA140Mu | ELISA Kit for Plasminogen Activator, Urokinase (uPA) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA140Mu | Multiplex Assay Kit for Plasminogen Activator, Urokinase (uPA) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |